Screener
LivaNova LIVN Neuromodulation — CapEx
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by LivaNova in its filing.
Tagged under the XBRL concept us-gaap:SegmentExpenditureAdditionToLongLivedAssets.
The source filing: LivaNova’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:23 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001639691-26-000090
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cardiopulmonary | $12,531 | $8,767 | $22,940 | $13,936 |
| Neuromodulation | 7,780 | 4,217 | 16,623 | 6,250 |
| Other capital expenditures (1) | 7,286 | 4,389 | 11,695 | 7,491 |
| $27,597 | $17,373 | $51,258 | $27,677 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is LivaNova's neuromodulation — capex?
- LivaNova (LIVN) reported neuromodulation — capex of $7.78M in Q2 2026.
- How has LivaNova's neuromodulation — capex changed year-over-year?
- LivaNova's neuromodulation — capex increased by 84.5% year-over-year, from $4.22M to $7.78M.
- What is the long-term trend for LivaNova's neuromodulation — capex?
- Over 4 years (2021 to 2025), LivaNova's neuromodulation — capex has grown at a 206.7% compound annual growth rate (CAGR), from $179K to $15.83M.
- What does neuromodulation — capex mean?
- Funds used by the Neuromodulation segment to acquire, upgrade, or maintain physical assets such as manufacturing equipment or laboratory facilities. It indicates the level of investment in infrastructure to sustain or expand production capacity.
Ask your AI about LivaNova's neuromodulation — capex.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude